at Zacks.com (Jan 12, 2015)
Teva Pharmaceutical (TEVA -0.2%) says data from its Phase III Glatiramer Acetate Low-Frequency Administration study shows a significant reduction in annual relapse rates and number of lesions in patients with relapsing-remitting multiple sclerosis, or RRMS. Detailed study results will be presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Lyon, France on October 13.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Jan 9, 2015)
at CNBC.com (Jan 5, 2015)
at Zacks.com (Dec 31, 2014)
at Nasdaq.com (Dec 31, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs